EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision

  title={EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision},
  author={Nadine Attal and Giorgio Cruccu and Ralf Baron and Maija L Haanp{\"a}{\"a} and Per T. Hansson and Troels Staehelin Jensen and Turo J. Nurmikko},
  journal={European Journal of Neurology},
BACKGROUND AND OBJECTIVES This second European Federation of Neurological Societies Task Force aimed at updating the existing evidence about the pharmacological treatment of neuropathic pain since 2005. [] Key Method All class I and II randomized controlled trials (RCTs) were assessed; lower class studies were considered only in conditions that had no top-level studies. Treatments administered using repeated or single administrations were considered, provided they are feasible in an outpatient setting…

Diagnosis and management of neuropathic pain.

A recent revision in the definition of neuropathic pain has highlighted this condition as a distinct disease entity and a multidisciplinary approach is recommended, with pharmacotherapy supplemented by psychological therapy and physical rehabilitation, and appropriate interventional treatment for selected refractory cases.

Neuropathic low back pain in clinical practice

This paper reviews the available literature on the role of neuropathic mechanisms in chronic LBP and discusses implications for its clinical management, with a particular focus on pharmacological treatments.

Is a Tricyclic Antidepressant the Best First-Line Agent in Treating Neuropathic Pain?

This poster presents a poster presented at the 2016 American Academy of Neurology Congress on the basis of evidence-based medicine and individualized patient care for the treatment of neuropathic pain.

Psychiatric co‐morbidities in patients with chronic peripheral neuropathic pain: A multicentre cohort study

Psychiatric co‐morbidities are common in patients with chronic pain, but no data are available about their prevalence in patients with neuropathic pain.

Does Duration of Neuropathic Pain Impact the Effectiveness of Pregabalin?

Patients with chronic pain conditions such as neuropathic pain frequently experience delays in diagnosis and treatment, but in those patients with more established disease it is important to know that approved treatments remain effective.

Pharmacological management of chronic neuropathic pain: Revised consensus statement from the Canadian Pain Society

This update to these guidelines for the treatment of neuropathic pain in the Canadian context incorporates new evidence published since the first guidelines were released in 2007.

Neuropathic component of pain in cancer

The prevalence of neuropathic pain in cancer patients is increasing as more patients are exposed to neurotoxic chemotherapies including taxane and platinum agents. Up to 40 % of cancer patients may

[Medical treatment of neuropathic pain].

  • Geir D SlapøJ. Schjøtt
  • Medicine, Psychology
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke
  • 2013
The most important drugs on which new treatment guidelines for neuropathic pain concur are presented, which suggest alternatives in the event of lack of effect or intolerable adverse effects.

European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision

To revise the 2010 consensus guideline on chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), the aim was to clarify the role of EMT and recommend a single treatment for CIDP patients.

Are there different predictors of analgesic response between antidepressants and anticonvulsants in painful diabetic neuropathy?

To investigate baseline demographics and disease characteristics as predictors of the analgesic effect of duloxetine and pregabalin on diabetic peripheral neuropathic pain (DPNP).



Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain

To evaluate the maintenance of effect of duloxetine 60 mg QD over 26 weeks in patients with diabetic peripheral neuropathic pain (DPNP).

Topiramate in painful diabetic polyneuropathy: findings from three double‐blind placebo‐controlled trials

Evaluation of the efficacy and tolerability of topiramate in patients with painful diabetic polyneuropathy and its use in clinical practice shows promising results.

Antidepressants for the treatment of neuropathic pain.

  • W. Cayley
  • Medicine, Psychology
    American family physician
  • 2006
Tricyclic antidepressants, particularly amitriptyline, are effective for the treatment of painful diabetic neuropathy and post herpetic neuralgia, and may be beneficial in other neuropathic pain

Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study

Objectives –  To evaluate the efficacy and safety of oxcarbazepine in patients with diabetic neuropathy in a multicenter, double‐blind, placebo‐controlled, dose‐ranging 16‐week study.


  • J. Ochoa
  • Medicine, Psychology
  • 2009
The clinical resemblance between patients with and without evidence of disease has been taken to indicate that both profiles are neuropathic, but the second profile is not.

Effect of levetiracetam on the postmastectomy pain syndrome

The aim of this randomized, double‐blind, placebo‐controlled, cross‐over study was to test whether levetiracetam relieves the postmastectomy pain syndrome.